<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) is a haematological disease currently classified in the category of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>/myeloproliferative <z:hpo ids='HP_0002664'>neoplasm</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN) because of its dual clinical and biological presentation </plain></SENT>
<SENT sid="1" pm="."><plain>The molecular biology of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> is poorly characterized </plain></SENT>
<SENT sid="2" pm="."><plain>We studied a series of 53 CMML samples including 31 cases of myeloproliferative form (MP-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) and 22 cases of myelodysplastic forms (MD-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) using array-comparative genomic hybridisation (aCGH) and sequencing of 13 candidate genes including ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, PTPN11, RUNX1, TET2 and WT1 </plain></SENT>
<SENT sid="3" pm="."><plain>Mutations in ASXL1 and in the genes associated with proliferation (CBL, FLT3, PTPN11, NRAS) were mainly found in MP-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> cases </plain></SENT>
<SENT sid="4" pm="."><plain>Mutations of ASXL1 correlated with an evolution toward an acutely transformed state: <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMMLs</z:e> that progressed to <z:hpo ids='HP_0011009'>acute</z:hpo> phase were mutated and none of the unmutated patients had evolved to <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>The overall survival of ASXL1 mutated patients was lower than that of unmutated patients </plain></SENT>
</text></document>